Investment objective & strategy
As of Oct. 9, 2025 · prospectusObjective. The investment objective of the F/m Emerald Special Situations ETF (the Fund) is to seek long-term growth through capital appreciation.
Strategy. The Fund is an actively managed exchange-traded fund (ETF) and invests primarily in equity securities of companies experiencing unique, idiosyncratic situations and transformations (Special Situations), selected by Emerald Mutual Fund Advisers Trust (the Sub-Adviser), the Funds investment sub-adviser, under the supervision of the Adviser. The Sub-Advisers research staff conducts company-specific research analysis to identify securities of the companies in which an unusual and possibly non-repetitive development is taking place which, in the opinion of the Sub-Adviser, may cause the securities to attain a higher market value independently, to a degree, than the trend in the securities market in general. Under normal market conditions, the Fund invests at least 80% of its net assets (plus the amount of any borrowings for … The Fund is an actively managed exchange-traded fund (ETF) and invests primarily in equity securities of companies experiencing unique, idiosyncratic situations and transformations (Special Situations), selected by Emerald Mutual Fund Advisers Trust (the Sub-Adviser), the Funds investment sub-adviser, under the supervision of the Adviser. The Sub-Advisers research staff conducts company-specific research analysis to identify securities of the companies in which an unusual and possibly non-repetitive development is taking place which, in the opinion of the Sub-Adviser, may cause the securities to attain a higher market value independently, to a degree, than the trend in the securities market in general. Under normal market conditions, the Fund invests at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in equity securities issued by companies experiencing Special Situations (the 80% Policy). The Fund considers that the Special Situation developments may include: ? Technological improvement or important discovery or acquisition which, if the expectation for it materialized, would effect a substantial change in the companys business; ? Corporate reorganization; ? Recapitalization or other development involving a security exchange or conversion; ? Material acquisition or transformational merger; ? Spin-out, divestiture, liquidation or distribution of cash, securities or other assets; ? Significant business model changes; ? Material change in ownership; ? Material or transformational contracts; ? Impacts from business/external disruptions; ? Litigation which, if resolved favorably, would improve the value of the companys stock; ? New or changed management; ? Price dislocation; ? Changes in governmental legislation, industry regulations, policy oversight; ? Macroeconomic and industry catalysts; and ? Positive or negative legislative or regulatory approvals or actions. The Sub-Advisers research process includes utilizing its proprietary 10-Step Research Process in prescreening potential investments. This includes, but is not limited to, the review of SEC filings, annual reports, financial statements, patents/other intellectual property, press releases and news stories, conducting surveys, monitoring patient groups, attending industry trade shows/conferences, meeting with management, interviewing customers, industry contacts, medical professionals, key opinion leaders, competitors, suppliers and distributors, developing financial and valuation models, reviewing third-party, peer-reviewed and internal research, and communicating and collaborating with fellow investment team members. The Fund can invest in companies from a wide range of industries and of various sizes. The Funds investment universe is not limited by market capitalization. Special Situations may often involve comparatively small companies which are not well known, and which have not been closely watched by investors generally, but may also involve larger companies. The Fund may invest in companies engaged in financial technology-related activities including decentralized finance and distributed ledger technology. Financial technology is the application of new technological advancements to products and services in the financial industry, seeking to improve and automate the delivery and use of financial services. Financial technology helps companies and consumers better manage their financial operations by utilizing specialized software. Financial technology companies compete with traditional financial methods in the delivery of financial services. Mobile banking, peer-to-peer lending, decentralized ledger technology and cryptocurrency are examples of financial technology. The Fund may also invest in companies that are engaged in the use of, or have exposure to, distributed ledger technology (DLT) and blockchain. The mechanics of using DLT, including blockchain, to transact in assets, including securities, is relatively new and untested and there is no assurance that widespread adoption will occur. Equity securities in which the Fund may invest include common stock, preferred stock, convertible preferred stock, shares of other investment companies and real estate investment trusts (REITs), and depositary receipts. The Fund may invest in shares of companies through private placements, warrants, rights, and initial public offerings. The Fund may invest in stocks of special purpose acquisition companies (SPACs). The Fund does not target a particular form of SPAC, with the exception that the SPAC must have identified an acquisition target at or prior to the time of the Funds investment. The Fund intends to invest primarily in U.S. companies, but it may invest up to 10% of its net assets in foreign companies listed on a U.S. exchange. A company is deemed to be a foreign company if one or more of the following tests are met: (i) the company is organized in, or its primary business office or principal trading market of its equity security is located outside the United States; (ii) a majority of the companys revenues are derived from outside the United States; or (iii) a majority of the issuers assets are located outside the United States. The Fund may invest in shares of companies through initial public offerings and private placements. The Fund generally sells investments when the Sub-Adviser concludes that better investment opportunities exist in other securities, the security is fully valued, or the issuers circumstances or the political or economic outlook have changed. The Fund has elected to be, and intends to continue to qualify each year for treatment as a regulated investment company (RIC) under Subchapter M of Subtitle A, Chapter 1, of the Internal Revenue Code of 1986, as amended (the Code).
Top holdings
As of April 30, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| CREDO TECHNOLOGY GROUP HOLDING LTD | — | $1.84M | 6.44% |
| TETRA TECHNOLOGIES INC | — | $1.26M | 4.41% |
| BLOOM ENERGY CORP CL A | — | $1.09M | 3.81% |
| SOLARIS OIL IN-A | — | $983.33K | 3.44% |
| AMER SUPERCONDTR | — | $935.88K | 3.27% |
| CARDINAL INFRA-A | — | $898.43K | 3.14% |
| NEKTAR THERAPEUTICS | — | $889.09K | 3.11% |
| AMAZON.COM INC | — | $863.04K | 3.02% |
| GUARDANT HEALTH INC | — | $844.41K | 2.95% |
| EXCELERATE ENERGY INC | — | $810.27K | 2.83% |
Portfolio moves
Jan 31, 2026 → Apr 30, 2026How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| Emerald Growth Fund | 25% | 0.78% |
| Polen 5Perspectives Small Growth Fund · PBSIX, PBSRX, PBSYX | 20% | 1.00% |
| F/m Emerald Life Sciences Innovation ETF · LFSC | 18% | 0.54% |
Footnotes
- Expense ratio as of October 9, 2025, from the fund's prospectus.
- Net assets and holdings count as of April 30, 2026, from the fund's N-PORT filing.
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.